SBIR-STTR Award

Visby - Formerlly known as Click Diagnostics - has developed a PCR based rapid disposable point of care test that automatically performs sample processing PCR amplification and amplicon detection Leveraging the existing platform Click will from a single urogenital sample detect NG and determine whether the infecting strain is susceptible to three classes of antibiotics ciprofloxacincefixime or a novel antibiotic zoliflodacin Because of the gonococci's ability to become resistant to almost every recommended antibiotic only one therapy is currently recommended by the CDC dual treatment with injectable ceftriaxone and oral azithromycin though reduced susceptibility has been observed for both By determining the genotype of the infecting strain WT gyraseA Serciprofloxacin susceptible or penA mosaic XXXIV reduced cefixime susceptibility we will be providing individualized treatment to patients thus minimizing the use of ceftriaxone Additionally by detecting zoliflodacin resistant genotypes gyraseB DN KT SNwe now have a companion diagnostic for this novel class of antibioticIn Phase IClick has partnered with Dr Jeffrey Klausner UCLA to develop and test a multiplexed antimicrobial susceptibility assay to detect single nucleotide polymorphisms that confer susceptibility resistance to ciprofloxacincefixime and zoliflodacin The new assay will retain similar specificity sensitivity PCR efficiency and limits of detection cfu mlas our current NG opaA assay